CERUS CORPORATION - CERUS - DEVELOPMENT AND IMPLEMENTATION OF PATHOGEN REDUCTION TECHNOLOGY (PRT). IGF::OT::IGF
Key Details
Description
CERUS - DEVELOPMENT AND IMPLEMENTATION OF PATHOGEN REDUCTION TECHNOLOGY (PRT). IGF::OT::IGF
Context & Analysis
On Feb 20, 2026, Department of Health and Human Services obligated $185,466,763.57 to CERUS CORPORATION for cerus - development and implementation of pathogen reduction technology (prt). igf::ot::igf. The award is classified under NAICS 541711 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY and issued as a cost no fee contract. Competition extent: full and open competition with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in CONCORD, CA. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541711 — related awards are listed below.
Market context
- Recompete outlook
- Ended Sep 30, 2026 (22 days ago). Recompete signal as of Oct 14, 2026: 22/100, combining time to the end date, the incumbent's history with this agency, whether the award was competed, and its size.
- Competition
- Competed, with 1 offer. 100% of 20 awards in this market (Department of Health and Human Services awards in NAICS 541711 over the last 3 years) were competed; median 2 offers.
- Award size
- At $185.5M, this award is larger than 19 in 20 of the 20 priced Department of Health and Human Services awards in NAICS 541711 over the last 3 years (median $4.3M).
- Largest vendors in this market
By obligations, Department of Health and Human Services awards in NAICS 541711 over the last 3 years.
- MEDICINES COMPANY, THE — 1 award, $98.1M
- JANSSEN VACCINES & PREVENTION B.V. — 1 award, $48.9M
- DNAE GROUP HOLDINGS LIMITED — 1 award, $43.4M
- AVITA MEDICAL AMERICAS, LLC — 1 award, $40.8M
- SRI INTERNATIONAL — 2 awards, $29.3M
Computed from USAspending award data on Oct 14, 2026.
Contractor Information
Similar Awards
THE MEDICINE COMPANY - ADVANCE THE DEVELOPMENT OF A PORTFOLIO OF ANTI-INFECTIVE PROGRAMS. IGF::OT::IGF
MEDICINES COMPANY, THE
$98.1M
IGF::OT::IGF
JANSSEN VACCINES & PREVENTION B.V.
$48.9M
IGF::OT::IGF - DNAE / PATHOGEN IDENTIFICATION FROM SPECIMEN, VIA CAPTURE, EXTRACTION AND SEQUENCING (PISCES)
DNAE GROUP HOLDINGS LIMITED
$43.4M
AUTOGRAFT-SPARING PRODUCTS FOR DEFINITIVE CARE OF BURN INJURIES
AVITA MEDICAL AMERICAS, LLC
$40.8M
IGF::OT::IGF POINT OF CARE BIODOSIMETRY TEST
SRI INTERNATIONAL
$25.5M
Stay Updated
Get notified about new opportunities matching your interests.